Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

2.

Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.

Asahina H, Sekine I, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T.

Clin Lung Cancer. 2012 Jan;13(1):39-43. doi: 10.1016/j.cllc.2011.06.010. Epub 2011 Sep 3.

PMID:
21890422
3.

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity.

Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, Mariotta S, Giarnieri E, Giovagnoli MR, Torrisi MR, Bergantino F, Costantini S, Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R.

J Transl Med. 2016 Feb 29;14:61. doi: 10.1186/s12967-016-0816-x.

4.

Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.

Dong X, Lin D, Low C, Vucic EA, English JC, Yee J, Murray N, Lam WL, Ling V, Lam S, Gout PW, Wang Y.

J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.

5.

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).

Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A.

Clin Transl Oncol. 2017 Mar;19(3):317-325. doi: 10.1007/s12094-016-1532-y. Epub 2016 Aug 4.

PMID:
27492015
6.

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE.

J Thorac Oncol. 2012 Oct;7(10):1594-601. doi: 10.1097/JTO.0b013e3182614835.

7.

Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer.

Tatli AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, Bozcuk HS.

J Cancer Res Ther. 2015 Oct-Dec;11(4):805-9. doi: 10.4103/0973-1482.146092.

8.

Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.

Malhotra J, Mhango G, Gomez JE, Smith C, Galsky MD, Strauss GM, Wisnivesky JP.

Ann Oncol. 2015 Apr;26(4):768-73. doi: 10.1093/annonc/mdv008. Epub 2015 Jan 18.

PMID:
25600562
9.

A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.

Uramoto H, Nakanishi R, Nagashima A, Uchiyama A, Inoue M, Osaki T, Yoshimatsu T, Sakata H, Nakanishi K, Yasumoto K.

Anticancer Res. 2010 Nov;30(11):4695-9.

PMID:
21115926
10.

Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers.

Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M.

Cancer Sci. 2003 Apr;94(4):394-9.

11.

A novel histopathological evaluation method predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy: the prognostic importance of the area of residual tumor.

Yamane Y, Ishii G, Goto K, Kojima M, Nakao M, Shimada Y, Nishiwaki Y, Nagai K, Kohrogi H, Ochiai A.

J Thorac Oncol. 2010 Jan;5(1):49-55. doi: 10.1097/JTO.0b013e3181c0a1f8.

12.

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.

Syrigos KN, Vansteenkiste J, Parikh P, von Pawel J, Manegold C, Martins RG, Simms L, Sugarman KP, Visseren-Grul C, Scagliotti GV.

Ann Oncol. 2010 Mar;21(3):556-61. doi: 10.1093/annonc/mdp392. Epub 2009 Oct 14.

PMID:
19828561
13.

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.

Kubota K, Sakai H, Katakami N, Nishio M, Inoue A, Okamoto H, Isobe H, Kunitoh H, Takiguchi Y, Kobayashi K, Nakamura Y, Ohmatsu H, Sugawara S, Minato K, Fukuda M, Yokoyama A, Takeuchi M, Michimae H, Gemma A, Kudoh S; Tokyo Cooperative Oncology Group..

Ann Oncol. 2015 Jul;26(7):1401-8. doi: 10.1093/annonc/mdv190. Epub 2015 Apr 23.

14.

Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.

Kogure Y, Ando M, Saka H, Chiba Y, Yamamoto N, Asami K, Hirashima T, Seto T, Nagase S, Otsuka K, Yanagihara K, Takeda K, Okamoto I, Aoki T, Takayama K, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K.

J Thorac Oncol. 2013 Jun;8(6):753-8. doi: 10.1097/JTO.0b013e31828b51f5.

15.

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.

Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, Button P, Gregory D, Solomon B, Dobrovic A, Do H, Clarke S.

Asia Pac J Clin Oncol. 2015 Mar;11(1):4-14. doi: 10.1111/ajco.12178. Epub 2014 Feb 27.

PMID:
24575793
16.

Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.

Jones DR, Moskaluk CA, Gillenwater HH, Petroni GR, Burks SG, Philips J, Rehm PK, Olazagasti J, Kozower BD, Bao Y.

J Thorac Oncol. 2012 Nov;7(11):1683-90. doi: 10.1097/JTO.0b013e318267928d.

17.

Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.

Tohda Y, Iwanaga T, Takada M, Yana T, Kawahara M, Negoro S, Okishio K, Kudoh S, Fukuoka M, Furuse K.

Chemotherapy. 1999 May-Jun;45(3):197-204.

PMID:
10224342
18.

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.

Komaki R, Scott CB, Sause WT, Johnson DH, Taylor SG 4th, Lee JS, Emami B, Byhardt RW, Curran WJ Jr, Dar AR, Cox JD.

Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):537-44.

PMID:
9336129
19.

Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer.

Jahnke K, Keilholz U, Lüftner D, Thiel E, Schmittel A.

Anticancer Res. 2011 Jan;31(1):317-23.

PMID:
21273617
20.

A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.

Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, RamLau R.

J Thorac Oncol. 2013 Mar;8(3):329-37. doi: 10.1097/JTO.0b013e31827ce554.

Supplemental Content

Support Center